Regulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic Targeting

被引:443
作者
Chaudhary, Belal [1 ]
Elkord, Eyad [2 ,3 ,4 ,5 ,6 ]
机构
[1] Univ Cambridge, Canc Res UK Cambridge Inst, Cambridge CB2 0RE, England
[2] Hamad Bin Khalifa Univ, Qatar Fdn, Qatar Biomed Res Inst, Ctr Canc, Doha 5825, Qatar
[3] Hamad Bin Khalifa Univ, Qatar Fdn, Coll Sci & Engn, Doha 5825, Qatar
[4] United Arab Emirates Univ, Coll Med & Hlth Sci, Al Ain 17666, U Arab Emirates
[5] Univ Manchester, Inst Canc Sci, Manchester M20 4BX, Lancs, England
[6] Univ Salford, Sch Environm & Life Sci, Biomed Res Ctr, Salford M5 4WT, Lancs, England
关键词
regulatory T cells; tumor microenvironment; cancer progression; therapeutic targeting; tumor-infiltrating lymphocytes; RECEPTOR; 4; ANTIBODY; SUPPRESSOR-CELLS; IMMUNE CELLS; FOXP3; EXPRESSION; CTLA-4; BLOCKADE; TGF-BETA; INFILTRATING LYMPHOCYTES; HEPATOCELLULAR-CARCINOMA; MONOCLONAL-ANTIBODY; METASTATIC MELANOMA;
D O I
10.3390/vaccines4030028
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
071005 [微生物学]; 100108 [医学免疫学];
摘要
Recent years have seen significant efforts in understanding and modulating the immune response in cancer. In this context, immunosuppressive cells, including regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs), have come under intense investigation for their proposed roles in suppressing tumor-specific immune responses and establishing an immunosuppressive tumor microenvironment, thus enabling tumor immune evasion. Additionally, recent evidence indicates that Tregs comprise diverse and heterogeneous subsets; phenotypically and functionally distinct subsets of tumor-infiltrating Tregs could contribute differently to cancer prognosis and clinical outcomes. Understanding Treg biology in the setting of cancer, and specifically the tumor microenvironment, is important for designing effective cancer therapies. In this review, we critically examine the role of Tregs in the tumor microenvironment and in cancer progression focusing on human studies. We also discuss the impact of current therapeutic modalities on Treg biology and the therapeutic opportunities for targeting Tregs to enhance anti-tumor immune responses and clinical benefits.
引用
收藏
页数:25
相关论文
共 172 条
[1]
Abd Al Samid M, 2016, ONCOTARGET, V7, P14083, DOI 10.18632/oncotarget.7334
[2]
Natural and induced T regulatory cells in cancer [J].
Adeegbe, Dennis O. ;
Nishikawa, Hiroyoshi .
FRONTIERS IN IMMUNOLOGY, 2013, 4
[3]
Ex vivo analysis of pancreatic cancer-infiltrating T lymphocytes reveals that ENO-specific Tregs accumulate in tumor tissue and inhibit Th1/Th17 effector cell functions [J].
Amedei, Amedeo ;
Niccolai, Elena ;
Benagiano, Marisa ;
Della Bella, Chiara ;
Cianchi, Fabio ;
Bechi, Paolo ;
Taddei, Antonio ;
Bencini, Lapo ;
Farsi, Marco ;
Cappello, Paola ;
Prisco, Domenico ;
Novelli, Francesco ;
D'Elios, Mario Milco .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2013, 62 (07) :1249-1260
[4]
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma [J].
Ansell, Stephen M. ;
Lesokhin, Alexander M. ;
Borrello, Ivan ;
Halwani, Ahmad ;
Scott, Emma C. ;
Gutierrez, Martin ;
Schuster, Stephen J. ;
Millenson, Michael M. ;
Cattry, Deepika ;
Freeman, Gordon J. ;
Rodig, Scott J. ;
Chapuy, Bjoern ;
Ligon, Azra H. ;
Zhu, Lili ;
Grosso, Joseph F. ;
Kim, Su Young ;
Timmerman, John M. ;
Shipp, Margaret A. ;
Armand, Philippe .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (04) :311-319
[5]
CD4+ T Effectors Specific for the Tumor Antigen NY-ESO-1 Are Highly Enriched at Ovarian Cancer Sites and Coexist with, but Are Distinct from, Tumor-Associated Treg [J].
Ayyoub, Maha ;
Pignon, Pascale ;
Classe, Jean-Marc ;
Odunsi, Kunle ;
Valmori, Danila .
CANCER IMMUNOLOGY RESEARCH, 2013, 1 (05) :303-308
[6]
SELECTIVE CHANGES IN THE IMMUNE PROFILE OF TUMOR-DRAINING LYMPH NODES AFTER DIFFERENT NEOADJUVANT CHEMORADIATION REGIMENS FOR LOCALLY ADVANCED CERVICAL CANCER [J].
Battaglia, Alessandra ;
Buzzonetti, Alexia ;
Martinelli, Enrica ;
Fanelli, Mara ;
Petrillo, Marco ;
Ferrandina, Gabriella ;
Scambia, Giovanni ;
Fattorossi, Andrea .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 76 (05) :1546-1553
[7]
T regulatory type 1 cells in squamous cell carcinoma of the head and neck: Mechanisms of suppression and expansion in advanced disease [J].
Bergmann, Christoph ;
Strauss, Laura ;
Wang, Yun ;
Szczepanski, Miroslaw J. ;
Lang, Stephan ;
Johnson, Jonas T. ;
Whiteside, Theresa L. .
CLINICAL CANCER RESEARCH, 2008, 14 (12) :3706-3715
[8]
Suppression of tumour-specific CD4+ T cells by regulatory T cells is associated with progression of human colorectal cancer [J].
Betts, Gareth ;
Jones, Emma ;
Junaid, Syed ;
El-Shanawany, Tariq ;
Scurr, Martin ;
Mizen, Paul ;
Kumar, Mayur ;
Jones, Sion ;
Rees, Brian ;
Williams, Geraint ;
Gallimore, Awen ;
Godkin, Andrew .
GUT, 2012, 61 (08) :1163-1171
[9]
Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer [J].
Bindea, Gabriela ;
Mlecnik, Bernhard ;
Tosolini, Marie ;
Kirilovsky, Amos ;
Waldner, Maximilian ;
Obenauf, Anna C. ;
Angell, Helen ;
Fredriksen, Tessa ;
Lafontaine, Lucie ;
Berger, Anne ;
Bruneval, Patrick ;
Fridman, Wolf Herman ;
Becker, Christoph ;
Pages, Franck ;
Speicher, Michael R. ;
Trajanoski, Zlatko ;
Galon, Jerome .
IMMUNITY, 2013, 39 (04) :782-795
[10]
Immunological correlates of treatment and response in stage IV malignant melanoma patients treated with Ipilimumab [J].
Bjoern, Jon ;
Nitschke, Nikolaj Juul ;
Iversen, Trine Zeeberg ;
Schmidt, Henrik ;
Fode, Kirsten ;
Svane, Inge Marie .
ONCOIMMUNOLOGY, 2016, 5 (04)